were obtained from the ratio of total T or E 2 (x toO) to SHBG concentrations.
All patients had elevated free 1'4 (range 41·8-120 pmol/L) and free 1'3 concentrations (range 25·7-36 pmol/L) and positive thyrotrophin receptor antibodies (range 33-4--76·3%; R.I.A.), before therapy. Plasma SHBG (mean 158·6 nmol/L, range 63·9-239· 3 nmol/L; normal range: to-50 nmol/L) and total T (mean 46·1 nmol/L, range 35·4-59·3 nmol/L; normal range:
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Thyrotoxicosis is associated with increased circulating sex hormone binding globulin (SHBG), total testosterone (T~, total oestradiol (~) and luteinising hormone. Although subtle evidence of gonadol dysfunction is well documented in thyrotoxic males/ the mechanism for these clinical and biochemical changes remains unclear. In an attempt to elucidate the mechanism we have studied four males with thyrotoxic Graves' disease (age range 21-53 years) by measuring serum free thyroxine (1'4), free triiodothyronine (1'3), SHBG, 1', E 2 , free androgen index (FAI), free oestrogen index (FEI), luteinising hormone (LH) and follicle stimulating hormone (FSH) at time of diagnosis and at 2 to 4-weekly intervals after commencement of treatment for a period of 3 months. One patient complained of mild breast tenderness, but none had gynaecomastia or loss of libido. Treatment with carbimazole was commenced in an initial dose of 10-15 mg 8-hourly with reduction to a maintenance level of 10 mg 12 hourly at 6 to 8-weeks based on clinical criteria.
Free 1'4 and 1'3 were measured using Arnerlex M kits, Radiochemical Centre, Amersham, Bucks, UK; SHBG by immuno-radiometric assay (mean coefficient of variation, CV 5%) Farmos' Diagnostica, Turku, Finland; total T and E 2 by radioimmuno assay (mean CV. 6·3% and 15·3%, respectively)-R.I.A., Washington, Tyne & Wear, UK; LH and FSH by radioimmunoassay (mean CV. 8·4% and 7·4%, respectively)-Chelsea Kit (Chelsea Hospital for Women, London SW3, UK). FAI and FEI 10·4-34·7 nmollL) were elevated in each patient. Total~was raised in one patient (365·5 pmollL) with upper normal values in the remainder (97·3-155'8 pmollL; normal range: 40-180 pmoI/L). The FAI was low in three patients(range 21)·9-33·6; median normal 75,2) and marginally reduced in the fourth (55·4). The FEI was decreased or low normal in all patients (range ()·()5-()· 31; median normal (}·37). Serum LII levels were elevated in three patients (range 12-48 lUlL; normal range: 1-10 lUlL) and normal in the remaining patient (3, 8 lUlL) and were inversely related to the FAI. FSH levels were raised (9 and 15 lUlL; normal range: 1-7 lUlL) in the two patients with the highest LH levels. No relationship was evident between gonadotrophin levels and either the FEI or the severity of thyrotoxicosis.
Treatment was associated with the expected fall in SHBG, total sex steroid levels and serum LH and a rise in FAI and FEI. The lag period in these changes was less then 2 weeks after reduction of thyroid hormone levels. An approximately linear relationship was evident between the fall in LII levels and rise in FAI in three patients ( Fig.) . This did not apply to the fourth patient who had a normal initial serum LH and an only marginally subnormal FAI.
These preliminary data in a small number of patients are consistent with the hypothesis that
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thyrotoxicosis induces an increase in SHBG synthesis; that free androgen falls as a result of increased binding and that reduced negative feedback increases LH secretion. A similar phenonemon has been suggested in thyrotoxic female patients.? Despite the increment in LH, free androgen levels would appear to remain low prior to treatment and this may reflect some impairment or resetting of Leydig cell responsiveness. Low free testosterone concentrations may explain the decreased libido and gynaecomastia which may accompany thyrotoxicosis. Our data do not support a role for oestrogen in mediating these effects.
